Johnson & Johnson vaccine is effective against against the Indian Delta variant and provides protection for eight months, pharma giant says
The New Jersey-based firm revealed that its vaccine is effective for up to eight months against the virus and is more effective against the Delta variant than the South African Beta variant.
However, the pharmaceutical giant said that its vaccine provides protection against all if the so-called ‘variants of concern’
‘Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally,’ said J&J Chief Scientific Officer Dr. Paul Stoffels in a statement.
‘We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.’
Johnson & Johnson has released preliminary data showing that its one-shot vaccine is effective against the hyperinfectious India Delta COVID variant.